140 related articles for article (PubMed ID: 38104352)
21. Prognostic significance of the MDM2/HMGA2 ratio and histological tumor grade in dedifferentiated liposarcoma.
Yamashita K; Kohashi K; Yamada Y; Akatsuka S; Ikuta K; Nishida Y; Toyokuni S; Oda Y
Genes Chromosomes Cancer; 2021 Jan; 60(1):26-37. PubMed ID: 33111425
[TBL] [Abstract][Full Text] [Related]
22. Establishment and characterization of NCC-DDLPS3-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Ono T; Sei A; Takeshita F; Sugaya J; Fukushima S; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2021 May; 34(3):1008-1018. PubMed ID: 33677797
[TBL] [Abstract][Full Text] [Related]
23. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.
Cornillie J; Wozniak A; Li H; Gebreyohannes YK; Wellens J; Hompes D; Debiec-Rychter M; Sciot R; Schöffski P
Clin Transl Oncol; 2020 Apr; 22(4):546-554. PubMed ID: 31201607
[TBL] [Abstract][Full Text] [Related]
24. Establishment and characterization of NCC-DDLPS1-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Sei A; Takeshita F; Sugaya J; Fukushima S; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2021 Jan; 34(1):260-270. PubMed ID: 32949334
[TBL] [Abstract][Full Text] [Related]
25. Degree of
Bill KLJ; Seligson ND; Hays JL; Awasthi A; Demoret B; Stets CW; Duggan MC; Bupathi M; Brock GN; Millis SZ; Shakya R; Timmers CD; Wakely PE; Pollock RE; Chen JL
Oncologist; 2019 Jul; 24(7):989-996. PubMed ID: 31019022
[TBL] [Abstract][Full Text] [Related]
26. SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.
Bill KL; Garnett J; Meaux I; Ma X; Creighton CJ; Bolshakov S; Barriere C; Debussche L; Lazar AJ; Prudner BC; Casadei L; Braggio D; Lopez G; Zewdu A; Bid H; Lev D; Pollock RE
Clin Cancer Res; 2016 Mar; 22(5):1150-60. PubMed ID: 26475335
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic alteration of p16INK4a gene in dedifferentiation of liposarcoma.
He M; Aisner S; Benevenia J; Patterson F; Harrison LE; Hameed M
Pathol Res Pract; 2009; 205(6):386-94. PubMed ID: 19186005
[TBL] [Abstract][Full Text] [Related]
28. Correlation of histological grade of dedifferentiation with clinical outcome in 55 patients with dedifferentiated liposarcomas.
Dantey K; Schoedel K; Yergiyev O; Bartlett D; Rao UNM
Hum Pathol; 2017 Aug; 66():86-92. PubMed ID: 28300575
[TBL] [Abstract][Full Text] [Related]
29. Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression drivers.
Cassinelli G; Pasquali S; Lanzi C
Front Oncol; 2022; 12():965261. PubMed ID: 36119484
[TBL] [Abstract][Full Text] [Related]
30. Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review.
Assi T; Kattan J; Rassy E; Nassereddine H; Farhat F; Honore C; Le Cesne A; Adam J; Mir O
Crit Rev Oncol Hematol; 2020 Sep; 153():103029. PubMed ID: 32593094
[TBL] [Abstract][Full Text] [Related]
31. Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study.
Abdul Razak AR; Bauer S; Suarez C; Lin CC; Quek R; Hütter-Krönke ML; Cubedo R; Ferretti S; Guerreiro N; Jullion A; Orlando EJ; Clementi G; Sand Dejmek J; Halilovic E; Fabre C; Blay JY; Italiano A
Clin Cancer Res; 2022 Mar; 28(6):1087-1097. PubMed ID: 34921024
[TBL] [Abstract][Full Text] [Related]
32. Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma.
Lu J; Wood D; Ingley E; Koks S; Wong D
Mol Biol Rep; 2021 Apr; 48(4):3637-3647. PubMed ID: 33893924
[TBL] [Abstract][Full Text] [Related]
33. Expression of the preadipocyte marker ZFP423 is dysregulated between well-differentiated and dedifferentiated liposarcoma.
Dang TN; Tiongco RP; Brown LM; Taylor JL; Lyons JM; Lau FH; Floyd ZE
BMC Cancer; 2022 Mar; 22(1):300. PubMed ID: 35313831
[TBL] [Abstract][Full Text] [Related]
34. Double minute chromosomes harboring MDM2 amplification in a pediatric atypical lipomatous tumor.
Dadone-Montaudié B; Burel-Vandenbos F; Soler C; Rosello O; Boyer C; Fabas T; Bianchini L; Pedeutour F
Genes Chromosomes Cancer; 2019 Sep; 58(9):673-679. PubMed ID: 30887579
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic Utility and Limitations of Immunohistochemistry of p16, CDK4, and MDM2 and Automated Dual-color In Situ Hybridization of MDM2 for the Diagnosis of Challenging Cases of Dedifferentiated Liposarcoma.
Kobayashi A; Sakuma T; Fujimoto M; Jimbo N; Hirose T
Appl Immunohistochem Mol Morphol; 2019; 27(10):758-763. PubMed ID: 31145104
[TBL] [Abstract][Full Text] [Related]
36. Detection of MDM2/CDK4 amplification in lipomatous soft tissue tumors from formalin-fixed, paraffin-embedded tissue: comparison of multiplex ligation-dependent probe amplification (MLPA) and fluorescence in situ hybridization (FISH).
Creytens D; van Gorp J; Ferdinande L; Speel EJ; Libbrecht L
Appl Immunohistochem Mol Morphol; 2015 Feb; 23(2):126-33. PubMed ID: 25679065
[TBL] [Abstract][Full Text] [Related]
37. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation.
Zuco V; Pasquali S; Tortoreto M; Brich S; Percio S; Dagrada GP; Colombo C; Sanfilippo R; Lauricella C; Gounder M; El Bezawy R; Barisella M; Dei Tos AP; Casali PG; Gronchi A; Stacchiotti S; Zaffaroni N
J Exp Clin Cancer Res; 2021 Mar; 40(1):83. PubMed ID: 33648535
[TBL] [Abstract][Full Text] [Related]
38. To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma.
Weiss MC; Eulo V; Van Tine BA
Clin Cancer Res; 2024 Feb; 30(4):649-651. PubMed ID: 38064245
[TBL] [Abstract][Full Text] [Related]
39. Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma.
Asano N; Yoshida A; Mitani S; Kobayashi E; Shiotani B; Komiyama M; Fujimoto H; Chuman H; Morioka H; Matsumoto M; Nakamura M; Kubo T; Kato M; Kohno T; Kawai A; Kondo T; Ichikawa H
Oncotarget; 2017 Feb; 8(8):12941-12952. PubMed ID: 28099935
[TBL] [Abstract][Full Text] [Related]
40. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?
Le Guellec S; Chibon F; Ouali M; Perot G; Decouvelaere AV; Robin YM; Larousserie F; Terrier P; Coindre JM; Neuville A
Am J Surg Pathol; 2014 Mar; 38(3):293-304. PubMed ID: 24525499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
